

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	SIGMA HEALTHCARE LIMITED ('Sigma')
ABN	15 088 417 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Vikesh RAMSUNDER
Date of last notice	20 December 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (j) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
Date of change	9 July 2024, 12 February 2025, 13 February 2025 and 14 February 2025
No. of securities held prior to change	11,662,028 fully paid ordinary shares (which includes 10,179,605 shares under Sigma's Loan Funded Share Plan) 1,482,422 Sign-On Rights 240,462 2022/2023 STI Rights 3,112,283 EEG Rights
Class	Rights to acquire fully paid ordinary shares in Sigma Fully paid ordinary shares in Sigma
Number acquired	1,253,717 rights 3,132,984 fully paid ordinary shares

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Number disposed	11,662,028 ordinary shares
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	<p>Acquired rights – the rights were granted under Sigma’s 2023/2024 STI Deferral Rights Plan and 2024 LTI Plan. Rights are issued for nil consideration and represent part of the employee incentive scheme component for Mr Ramsunder.</p> <p>Acquired shares – shares issued on the exercise of existing rights. No consideration is payable by the holder to Sigma on the exercise of a right. The corresponding rights lapse upon issuance of the shares.</p> <p>Disposed shares – average price of \$2.92 per share</p>
No. of securities held after change	3,132,984 fully paid ordinary shares 1,010,723 2024 LTI Rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<p>Issuance of rights under Sigma’s 2023/2024 STI Deferral Rights Plan (242,994 rights) and 2024 LTI Plan (1,010,723 rights) on 9 July 2024.</p> <p>Conversion of 1,167,106 EEG Rights to ordinary shares and lapse of remaining 1,945,177 EEG Rights (replaced by a cash bonus of equivalent value) on 12 February 2025 in accordance with treatment under merger with Chemist Warehouse (see section 6.5.3.2 of Sigma’s prospectus dated 10 February 2025)</p> <p>On-market disposal of shares on 13 February 2025 (1,482,423 ordinary shares and 10,179,605 LFSP shares)</p> <p>Exercise of rights and corresponding issuance of shares on 14 February 2025 (1,482,422 sign-on rights, 240,462 2022/2023 STI Rights and 242,994 2023/2024 STI Rights)</p>

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
---------------------------	-----

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	Yes, however see Sigma's ASX announcement of a Special Dispensation Period dated 12 February 2025 https://investorcentre.sigmahealthcare.com.au/static-files/db7ea038-9c8e-4fc0-aa9a-e4c51ec72f95
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.

For personal use only